Resources

Check out the National Blood Clot Alliance's educational webpages and related materials on Thrombophilia Clotting Risks, part of www.stoptheclot.org – an excellent resource for patients and their families.

Register for a local meeting near you as part of our Clinical Connections™ Series:

TITLE: Reducing the Risk of Hospital-Acquired Venous Thromboembolism in Your Surgical Patients


Intended Audience: Cardiovascular Surgery, Critical Care, and VTE Quality Teams


Upcoming Meetings:
December 8, 2018 – New York, NY


Registration information:


Register online


If you prefer to register by phone, or if you have any questions, please call 1-919-534-2200 or 1-877-870-9060.


Keep checking back because we update with new events monthly!

Visit us at these conferences and symposiums

December 01, 2018

San Diego, CA

American Society of Hematology


December 07, 2018

New York, NY

PostGraduate Assembly in Anesthesiology


On Saturday, December 8th, be sure to attend the Grifols-sponsored symposium, Reducing the Risk of Hospital-Acquired Venous Thromboembolism in Your Surgical Patients.


IMPORTANT SAFETY INFORMATION


THROMBATE III® (antithrombin III [human]) is indicated in patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism.

Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment.

Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product.

Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays.

In clinical studies, the most common adverse reactions (≥ 5% of subjects) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps).

The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III.

Please see full Prescribing Information for THROMBATE III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.